REZLIDHIA (olutasidenib), FDA-Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., Dec. 19, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Rigel Pharmaceuticals as one of two specialty pharmacies in a limited distribution network for REZLIDHIATM (olutasidenib), which is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) […]